PeptideJournal
Peptide Profiles19 min read

GHRP-6: Growth Hormone Peptide Research

GHRP-6 (Growth Hormone-Releasing Peptide-6) stands as one of the pioneering synthetic peptides developed to stimulate natural growth hormone release.

GHRP-6 (Growth Hormone-Releasing Peptide-6) stands as one of the pioneering synthetic peptides developed to stimulate natural growth hormone release. Originally created in the 1980s, this hexapeptide marked a significant advancement in peptide therapeutics, though its clinical trajectory has shifted from simple growth hormone elevation toward cytoprotective applications. Unlike isolated growth hormone administration, GHRP-6 works by activating the body's ghrelin receptor system, which makes it notably different from other growth hormone secretagogues in both mechanism and effect profile.

What sets GHRP-6 apart is its strong ghrelin-mimetic activity. This means it doesn't just trigger growth hormone release—it also significantly increases appetite and raises other hormones like cortisol and prolactin at higher doses. These characteristics make it both useful and limiting, depending on the clinical context. While Ipamorelin was later developed to provide selective GH release without these additional effects, GHRP-6 remains scientifically important for its cardioprotective, wound healing, and anti-fibrotic properties demonstrated in research settings.

This article examines the scientific evidence behind GHRP-6, from its molecular mechanisms to its clinical research applications, safety profile, and regulatory status.

Table of Contents

  1. Quick Facts
  2. What Is GHRP-6?
  3. Mechanisms of Action
  4. Research Evidence
  5. Safety and Side Effects
  6. Legal and Regulatory Status
  7. Frequently Asked Questions
  8. The Bottom Line

Quick Facts

PropertyDetails
Chemical NameGrowth Hormone-Releasing Peptide-6
Alternative NamesGHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
Peptide ClassGrowth Hormone Secretagogue (Ghrelin Receptor Agonist)
SequenceHis-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH₂
Molecular Weight873 Daltons
Molecular FormulaC₄₆H₅₆N₁₂O₆
Primary ReceptorGHS-R1a (Ghrelin Receptor), CD36
Half-LifeApproximately 2.5 hours
FDA StatusNot FDA-approved; research use only
Notable PropertiesStrong appetite stimulation, cardioprotective effects, anti-fibrotic activity

What Is GHRP-6?

GHRP-6 is a synthetic hexapeptide—a chain of six amino acids—developed as part of early research into growth hormone-releasing peptides. It belongs to the class of growth hormone secretagogues (GHSs), compounds that stimulate the pituitary gland to release growth hormone. GHRP-6 was among the first synthetic peptides to demonstrate potent and reproducible growth hormone-releasing activity in both animal models and human clinical studies.

Chemical Structure

The peptide sequence is His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH₂, with a molecular mass of 873 Dalton. The inclusion of D-amino acids (unnatural mirror-image forms) at positions 2 and 5 makes the peptide resistant to enzymatic breakdown, extending its biological activity compared to natural peptides.

Historical Development

GHRP-6 emerged from research on met-enkephalin analogues in the 1980s. Scientists were searching for compounds that could stimulate growth hormone release through a mechanism distinct from growth hormone-releasing hormone (GHRH). Early studies revealed that GHRP-6 could elicit dose-related GH release both in vitro and in vivo, marking it as a first-generation growth hormone secretagogue.

How It Differs from Other Peptides

Unlike growth hormone-releasing hormone (GHRH) peptides such as Sermorelin or CJC-1295, which work through GHRH receptors on pituitary cells, GHRP-6 acts on ghrelin receptors. This dual pathway—acting both at the hypothalamic and pituitary levels—distinguishes it from GHRH peptides.

GHRP-6 also differs substantially from later-generation GHRPs. While Ipamorelin was engineered for selective GH release without affecting cortisol or prolactin, GHRP-6 raises these hormones at moderate to high doses. It also produces marked appetite stimulation due to its ghrelin-mimetic properties, whereas Ipamorelin does not significantly affect hunger.

Current Research Focus

While GHRP-6 was initially developed as an anabolic and anti-aging compound, clinical interest has shifted toward its cytoprotective properties. Research now focuses on its cardioprotective effects in ischemia-reperfusion injury, its anti-fibrotic properties in wound healing, and its potential role in preventing organ damage from chemotherapy or ischemic events.

Mechanisms of Action

GHRP-6 exerts its effects through several interconnected molecular pathways, primarily centered on ghrelin receptor activation but extending to other receptor systems and signaling cascades.

Ghrelin Receptor Activation (GHS-R1a)

The primary mechanism of GHRP-6 is its action as a synthetic agonist of the ghrelin receptor (GHS-R1a). Ghrelin is known as the "hunger hormone," but it also plays a critical role in regulating growth hormone secretion. When GHRP-6 binds to GHS-R1a receptors on cells in the hypothalamus and pituitary gland, it triggers a signaling cascade that results in pulsatile growth hormone release.

Interestingly, GHRP-6 shows no sequence homology with natural ghrelin, yet both activate the same receptor. Structural studies have revealed how GHRP-6 binds to the receptor's active site and initiates conformational changes that mimic ghrelin's effects.

Growth Hormone Release Pathway

At the hypothalamic level, GHRP-6 stimulates neurons that produce growth hormone-releasing hormone (GHRH). At the pituitary level, it directly acts on somatotroph cells. Research shows that GHRP-6 stimulates phosphatidylinositol turnover, a second messenger system that activates protein kinase C and mobilizes intracellular calcium reserves. This calcium influx is essential for vesicle fusion and hormone secretion.

Crucially, studies demonstrate that endogenous GHRH is necessary for most of the GH response to GHRP-6. This means GHRP-6 works synergistically with the body's natural GHRH system rather than replacing it. When combined with GHRH analogs like CJC-1295, the GH response is amplified through complementary pathways.

CD36 Receptor Pathway

Beyond the ghrelin receptor, GHRP-6 also activates CD36, a scavenger receptor found on various cell types including cardiomyocytes, macrophages, and fibroblasts. The cardioprotective effects of GHRP-6 are mediated by stimulation of both GHS-R1a and CD36 receptors. Activation of CD36 protects against myocardial damage from ischemia-reperfusion injury and modulates inflammatory responses.

In wound healing, CD36 activation by GHRP-6 attenuates inflammation, accelerates wound closure, and improves esthetic outcomes by impacting extracellular matrix protein accumulation.

Appetite and Metabolic Effects

Because GHRP-6 activates ghrelin receptors, it produces the hunger-inducing effects associated with ghrelin itself. Research in animal models shows that GHRP-6 mimics ghrelin-induced stimulation of food intake and affects locomotor activity. This appetite stimulation typically occurs within 15-30 minutes of administration and can be substantial.

The peptide also influences gastric motility. Studies in diabetic mice demonstrated that GHRP-6 significantly accelerated gastric emptying and intestinal transit, suggesting prokinetic effects that could benefit patients with gastroparesis or delayed gastric emptying.

Anti-Fibrotic Mechanisms

GHRP-6's anti-fibrotic properties involve activation of PPARγ (peroxisome proliferator-activated receptor gamma) and modulation of fibrogenic cytokine expression. In hypertrophic scar models, GHRP-6 reduced expression of TGF-β1 and CTGF, two key drivers of fibrosis, while increasing expression of PPARγ and MMP-13, which help remodel accumulated fibrotic tissue.

Cardioprotective Signaling

In cardiac tissue, GHRP-6 activates prosurvival pathways that protect cardiomyocytes from oxidative stress and apoptosis. It reduces reactive oxygen species production and preserves antioxidant defense systems, mechanisms particularly important during ischemia-reperfusion events when oxygen suddenly returns to previously ischemic tissue.

Research Evidence

Scientific investigation of GHRP-6 spans multiple domains, from growth hormone dynamics to tissue protection and wound healing. While initial research focused on its GH-releasing properties, more recent work has examined its broader cytoprotective effects.

Growth Hormone Release Studies

Human Clinical Trials

A pharmacokinetic study in nine healthy male volunteers examined GHRP-6 at doses of 100, 200, and 400 μg/kg administered intravenously. The peptide demonstrated a distribution half-life of 7.6 ± 1.9 minutes and an elimination half-life of 2.5 ± 1.1 hours. All doses were well tolerated with no serious adverse effects reported.

Clinical studies comparing GHRP-6 to GHRH found that while both stimulate GH release, GHRP-6 requires endogenous GHRH for maximal effect. In patients with hypothalamic-pituitary disconnection, where GHRH neurons are severed, GHRP-6 loses much of its GH-releasing activity. This confirms that GHRP-6 primarily works by amplifying natural GH pulses rather than creating entirely independent secretion events.

Comparison with GHRH in Special Populations

Research in patients with primary hypothyroidism found they had higher GH responses to GHRP-6 than to GHRH compared to controls. This suggests the ghrelin receptor pathway may be upregulated or more responsive in certain endocrine disorders.

Studies examining GH responses during sleep found that repeated intravenous boluses of GHRP-6 increased serum GH, ACTH, and cortisol levels, with effects on sleep architecture that differed based on route of administration (intravenous versus subcutaneous).

Cardioprotective Research

The cardioprotective effects of GHRP-6 represent some of the most compelling research findings.

Acute Myocardial Infarction Models

In a porcine model of acute myocardial infarction, GHRP-6 reduced infarct size by over 70%. Infarct mass and thickness were reduced by 78% and 50% respectively compared with saline controls. The peptide prevented oxidative cytotoxicity and reduced myocardial necrosis through preservation of antioxidant defense systems.

A 2024 study examining doxorubicin-induced cardiac damage found that GHRP-6 administration prevented myocardial fiber loss and ventricular dilation, preserving left ventricular systolic function. The peptide also protected epithelial organs, inhibited interstitial fibrosis, and reduced morbidity and mortality in treated animals.

Mechanisms of Cardiac Protection

Research demonstrates that GHRP-6's cardioprotective effects are mediated through both GHS-R1a and CD36 receptors. Activation of CD36 is particularly important for protecting against ischemia-reperfusion injury. The peptide suppresses cardiomyocyte apoptosis, reduces reactive oxygen species, and improves left ventricular function and remodeling in chronic heart failure models.

Studies in rats with heart failure showed that GH-releasing peptides, including GHRP-6, improved cardiac dysfunction and cachexia while suppressing stress-related hormones and cardiomyocyte apoptosis.

Wound Healing and Anti-Fibrotic Effects

Hypertrophic Scar Prevention

In a rabbit hypertrophic scar model, GHRP-6 prevented the onset of keloid-like scars in more than 90% of treated wounds. The intervention dramatically reduced exuberant scar formation by activating PPARγ and reducing expression of fibrogenic cytokines. GHRP-6 prevented parenchymal fibrotic induration in more than 85% of cases and removed approximately 75% of accumulated fibrotic material.

Molecular analysis revealed that GHRP-6 decreased transcriptional expression of pro-fibrotic genes TGF-β1 and CTGF while inducing expression of PPARγ and MMP-13, genes relevant for inhibiting pathological accumulation processes.

Timing and Limitations

The anti-fibrotic effects appear most pronounced when GHRP-6 is applied immediately after injury. Research shows GHRP-6 had no effect on the reversion of consolidated lesions, meaning it works preventively rather than therapeutically on established scars. While effective at preventing hypertrophic scars without the adverse reactions of corticosteroids like triamcinolone acetonide, it failed to significantly reverse mature hypertrophic scars.

Organ Protection and Multi-Organ Failure Prevention

Studies examining intestinal and hepatic ischemia-reperfusion injury found that pre-treatment with GHRP-6 at 120 μg/kg intraperitoneally reduced organ damage markers by 50-85%. The peptide exhibited potent cytoprotective effects, extending tissue viability during acute ischemia-reperfusion episodes in multiple organs including small bowel, liver, and kidneys.

Body Composition and Metabolic Effects

Research examining weight gain and fat mass accrual found that positive effects of GHRP-6 on these parameters depend on insulin/glucose status. The peptide's appetite-stimulating properties can promote weight gain, which may be beneficial in cachexia or wasting conditions but less desirable in other contexts.

Comparative Studies: GHRP-6 vs. Other Secretagogues

Studies comparing GHRP-6 to Ipamorelin reveal important differences. Both peptides release growth hormone at similar speeds and strengths, but Ipamorelin is highly selective, inducing GH release without significantly affecting ACTH, cortisol, or prolactin—even at doses 200-fold higher than the effective dose for GH release. In contrast, GHRP-6 increases cortisol and prolactin along with GH at higher doses.

GHRP-6 also causes significant appetite stimulation, while Ipamorelin does not produce the ravenous hunger characteristic of GHRP-6. This makes GHRP-6 potentially useful in clinical situations involving cachexia or malnutrition but less ideal when appetite stimulation is undesired.

Compared to GHRP-2 and Hexarelin, GHRP-6 shows intermediate effects on cortisol and prolactin. Hexarelin tends to produce the strongest elevations of these hormones, while GHRP-2 falls between Hexarelin and GHRP-6. Ipamorelin was specifically developed to avoid these non-selective effects entirely.

Safety and Side Effects

GHRP-6 has been studied in clinical trials involving healthy volunteers and specific patient populations. While generally well-tolerated at research doses, it produces several predictable effects related to its mechanism of action.

Common Effects

Appetite Stimulation: The most consistent and noticeable effect is increased hunger, typically occurring within 15-30 minutes of administration. This results from GHRP-6's activation of ghrelin receptors, which signal hunger to the brain. For some research contexts, this is beneficial; for others, it's undesirable.

Water Retention: Mild fluid retention can occur due to growth hormone's effects on sodium and water balance. This is typically transient and resolves with continued use or dose adjustment.

Injection Site Reactions: Subcutaneous administration may cause temporary redness, swelling, or discomfort at injection sites. Rotating injection sites and proper technique minimize these effects.

Hormonal Effects

Cortisol and Prolactin Elevation: GHRP-6 can increase cortisol and prolactin secretion, particularly at doses above 100 μg. Research shows these increases are dose-dependent and less pronounced than with Hexarelin but more significant than with Ipamorelin.

Studies found that cortisol and prolactin increases were not significantly altered at doses of 100 μg or less, but higher doses elevate these hormones. Prolonged elevation of cortisol can affect mood, energy, immune function, and metabolism. Elevated prolactin may cause mood changes and, in rare cases, gynecomastia in males.

ACTH Stimulation: Repeated doses of GHRP-6 increase ACTH along with cortisol, indicating activation of the hypothalamic-pituitary-adrenal axis.

Safety in Clinical Trials

A dose-escalation safety study examined GHRP-6 at 100, 200, and 400 μg/kg intravenously in healthy volunteers. All doses were well tolerated with no serious adverse events. This suggests a favorable safety profile within the dose ranges studied, though long-term safety data in humans remains limited.

Contraindications and Cautions

Cancer: As with all growth hormone secretagogues, there are theoretical concerns about stimulating cell proliferation in individuals with active cancer or pre-malignant conditions. No direct evidence links GHRP-6 to cancer promotion, but caution is warranted.

Diabetes: GHRP-6's effects on glucose metabolism and insulin sensitivity require careful consideration in diabetic populations. Studies in diabetic mice showed prokinetic benefits, but glucose monitoring would be essential in human diabetic patients.

Pregnancy and Lactation: No safety data exists for GHRP-6 use during pregnancy or breastfeeding. Given the peptide's hormonal effects, use should be avoided in these populations.

Long-Term Considerations

Receptor Desensitization: With continuous use, ghrelin receptors may become less responsive to stimulation. Cycling protocols or pulsatile dosing strategies are often employed in research settings to maintain responsiveness.

Hormonal Balance: Chronic elevation of GH, particularly without cycling, can affect thyroid function, insulin sensitivity, and other hormonal axes. Monitoring would be necessary for extended use.

Comparison with Other GHRPs

From a side-effect perspective, GHRP-6 falls in the middle range. Hexarelin produces the strongest effects on cortisol and prolactin, GHRP-6 and GHRP-2 produce moderate effects, and Ipamorelin produces minimal to no effects on these hormones. For research focused solely on GH elevation without appetite stimulation or cortisol/prolactin effects, Ipamorelin represents a more selective option.

Research Use Only

It's critical to note that GHRP-6 is not FDA-approved for human therapeutic use. All available safety data comes from research studies, and the long-term effects of chronic use in various populations remain unknown. Multiple sources emphasize that GHRP-6 is intended for research purposes only.

GHRP-6 occupies a complex position in the regulatory landscape, characterized by lack of FDA approval and active enforcement against its compounding and distribution.

FDA Approval Status

GHRP-6 is not FDA-approved for human use. It is not the subject of an applicable USP or NF monograph, is not a component of any FDA-approved human drug, and does not appear on the 503A bulks list (substances that compounding pharmacies under section 503A can legally use).

Drug products compounded using GHRP-6 are not eligible for exemptions provided by section 503A(a) of the Federal Food, Drug, and Cosmetic Act (FDCA) and are therefore subject to FDA approval requirements under section 505 of the FDCA.

Compounding Pharmacy Restrictions

GHRP-6 was nominated for inclusion on the 503B bulks list (which applies to outsourcing facilities) but without adequate support for the FDA to evaluate the substance. As a result, compounding pharmacies cannot legally compound GHRP-6 products.

The FDA has issued multiple warning letters to compounding pharmacies for producing drug products containing GHRP-6. Warning letters were issued to facilities including ImprimisRx in March 2019 and United Pharmacy in February 2019, among others. These enforcement actions indicate the FDA's position is clear and actively enforced.

Current Availability

Despite regulatory restrictions, GHRP-6 remains available through some compounding pharmacies and peptide research supply companies, though this exists in a regulatory gray area. Vendors typically market it explicitly "for research use only" or "not for human consumption" to navigate FDA restrictions.

Clinicians prescribing compounded GHRP-6 and pharmacies compounding it do so outside the regulatory framework that normally governs drug products, potentially exposing themselves to legal risk.

International Status

Regulatory status varies internationally. Some countries permit compounding or off-label use of peptides not approved domestically, while others have stricter controls. Anyone considering research with GHRP-6 must verify the legal status in their jurisdiction.

Research Context

In legitimate research settings—universities, pharmaceutical companies, preclinical studies—GHRP-6 can be used under appropriate institutional review board oversight and regulatory frameworks governing experimental compounds. The peptide remains a valuable research tool for understanding growth hormone regulation, ghrelin receptor pharmacology, and cytoprotective mechanisms.

Anti-Doping Regulations

GHRP-6 is prohibited by the World Anti-Doping Agency (WADA) under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes subject to anti-doping testing can face sanctions for GHRP-6 use. The peptide is detectable through specialized testing methods.

Future Prospects

While GHRP-6 itself has not advanced through FDA approval pathways, research into its cytoprotective mechanisms could inform development of related compounds or formulations that might pursue approval for specific indications like wound healing, cardiac ischemia, or organ protection.

Frequently Asked Questions

What is GHRP-6 used for?

GHRP-6 is a research peptide studied for its growth hormone-releasing properties, cardioprotective effects, wound healing benefits, and anti-fibrotic activity. It is not FDA-approved for any therapeutic use in humans. Research has focused on its potential applications in cardiac ischemia-reperfusion injury, prevention of hypertrophic scarring, protection against chemotherapy-induced organ damage, and appetite stimulation in cachexia or wasting conditions.

How does GHRP-6 compare to Ipamorelin?

Both GHRP-6 and Ipamorelin stimulate growth hormone release, but they differ significantly in selectivity and side effects. Ipamorelin is highly selective for GH release and does not significantly affect cortisol or prolactin, even at high doses. GHRP-6, by contrast, increases cortisol and prolactin at moderate to high doses. GHRP-6 also causes marked appetite stimulation due to its ghrelin-mimetic properties, while Ipamorelin does not produce significant hunger effects. For research focused purely on GH elevation without appetite or hormonal side effects, Ipamorelin is preferable. For research where appetite stimulation or broader ghrelin receptor effects are desired, GHRP-6 may be more appropriate.

Does GHRP-6 cause hunger?

Yes, GHRP-6 significantly increases appetite, typically within 15-30 minutes of administration. This occurs because GHRP-6 activates ghrelin receptors, the same receptors activated by ghrelin—the body's primary hunger hormone. The appetite stimulation can be substantial and is one of GHRP-6's most consistent effects. This property makes it potentially useful in research contexts involving cachexia, malnutrition, or wasting syndromes where appetite stimulation is desired, but less suitable for contexts where increased hunger would be problematic.

What are the cardioprotective effects of GHRP-6?

GHRP-6 has demonstrated significant cardioprotective properties in preclinical research. In models of acute myocardial infarction, it reduces infarct size by over 70%, prevents myocardial fiber loss, preserves left ventricular function, and reduces mortality. The mechanisms involve activation of both ghrelin receptors (GHS-R1a) and CD36 receptors on cardiac cells, leading to reduced oxidative stress, preservation of antioxidant systems, suppression of cardiomyocyte apoptosis, and improved cardiac remodeling. GHRP-6 also protects against doxorubicin-induced cardiac toxicity, a significant concern in chemotherapy.

Can GHRP-6 prevent scarring?

Research in animal models shows that GHRP-6 can prevent hypertrophic scar formation when applied immediately after injury. In rabbit models, it prevented keloid-like scars in over 90% of treated wounds by activating PPARγ and reducing expression of fibrogenic cytokines like TGF-β1 and CTGF. However, GHRP-6 showed no effect on reversing established, mature scars. Its anti-fibrotic effects are preventive rather than therapeutic, working by modulating the inflammatory and fibrotic response during active wound healing. This makes timing critical—GHRP-6 must be applied during the acute wound healing phase to be effective.

What are the side effects of GHRP-6?

The most common effects include significant appetite increase, mild water retention, and injection site reactions. At higher doses (above 100 μg), GHRP-6 can elevate cortisol and prolactin levels, which may cause mood changes, fatigue, or (rarely) gynecomastia with prolonged use. Clinical safety studies showed GHRP-6 was well tolerated at doses up to 400 μg/kg with no serious adverse events, though long-term human safety data is limited. Theoretical concerns exist for individuals with active cancer (due to growth hormone's proliferative effects) and diabetics (due to effects on glucose metabolism).

GHRP-6 is not FDA-approved and cannot legally be compounded by pharmacies under section 503A or 503B of the FDCA. The FDA has issued warning letters to compounding pharmacies distributing GHRP-6 products. It is available through research chemical suppliers marketed explicitly "for research use only," but this does not constitute legal human therapeutic use. GHRP-6 is also prohibited by WADA for athletes subject to anti-doping regulations. In legitimate research settings (universities, pharmaceutical companies), it can be used under appropriate institutional and regulatory oversight.

How is GHRP-6 administered?

In clinical research studies, GHRP-6 has been administered via intravenous, subcutaneous, intramuscular, intranasal, and oral routes. Subcutaneous and intravenous administration are most common in research protocols. The peptide has a relatively short half-life of approximately 2.5 hours, with a distribution phase of about 7.6 minutes. Research protocols typically employ multiple daily doses to maintain elevated GH levels. Doses studied in human trials range from 100 to 400 μg/kg, with optimal timing on an empty stomach (2-3 hours after meals, 30 minutes before eating) to maximize GH response.

The Bottom Line

GHRP-6 represents a pioneering chapter in peptide therapeutics, one of the first synthetic compounds to demonstrate potent and reproducible growth hormone release through the ghrelin receptor system. While its original promise as an anabolic and anti-aging agent has not translated to clinical approval, GHRP-6 has revealed unexpected therapeutic potential in cytoprotection—particularly in cardiac ischemia, wound healing, and organ protection from toxic or ischemic injury.

The scientific evidence is compelling in specific domains. Cardioprotective studies show dramatic reductions in infarct size and improvements in cardiac function. Wound healing research demonstrates significant anti-fibrotic effects and prevention of hypertrophic scarring. These findings suggest GHRP-6's value lies not in simple growth hormone elevation but in its broader cellular protective effects mediated through both ghrelin and CD36 receptors.

However, GHRP-6's limitations are equally clear. Its strong appetite-stimulating properties and effects on cortisol and prolactin make it less selective than later-generation peptides like Ipamorelin. Its lack of FDA approval, combined with active regulatory enforcement against compounding, places it firmly in the realm of research tools rather than established therapeutics.

For researchers, GHRP-6 remains valuable for understanding growth hormone regulation, ghrelin receptor pharmacology, and mechanisms of cytoprotection. For clinicians and patients, it represents an unapproved experimental compound with promising preclinical data but insufficient clinical evidence and regulatory standing for therapeutic use.

The future may lie in derivatives or formulations that capture GHRP-6's protective effects while minimizing unwanted properties—selective CD36 agonists for cardiac protection, or refined anti-fibrotic peptides for wound healing. Until such developments reach clinical approval, GHRP-6's role remains confined to the laboratory and the margins of peptide research.

Medical Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice. GHRP-6 is not FDA-approved for human use and is available only for research purposes. The information presented is based on scientific literature and clinical studies but should not be interpreted as an endorsement or recommendation for use.

Anyone considering research involving GHRP-6 should consult qualified medical professionals and verify legal and regulatory status in their jurisdiction. Peptide research should only be conducted under appropriate institutional oversight and regulatory frameworks. PeptideJournal.org does not sell peptides or advocate for their use outside legitimate research contexts.

References

  1. Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clinical Medicine Insights: Cardiology. 2017.

  2. Bowers CY, et al. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. Endocrinology. 1995.

  3. Popovic V, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. Journal of Clinical Endocrinology & Metabolism. 1995.

  4. Xu X, et al. Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor. Nature Communications. 2021.

  5. Broglio F, et al. GHRP-6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity in goldfish. Peptides. 2012.

  6. Delporte C. Prokinetic effects of a ghrelin receptor agonist GHRP-6 in diabetic mice. American Journal of Physiology. 2009.

  7. Laron Z, et al. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism. Clinical Endocrinology. 1997.

  8. Frieboes RM, et al. Effects of Growth Hormone-Releasing Peptide-6 on the Nocturnal Secretion of GH, ACTH and Cortisol and on the Sleep EEG in Man. Journal of Neuroendocrinology. 1999.

  9. Arvat E, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.

  10. Raun K, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000.

  11. Granado M, et al. Positive Effects of Growth Hormone-Releasing Peptide-6 on Weight Gain and Fat Mass Accrual Depend on the Insulin/Glucose Status. Endocrinology. 2010.

  12. Berlanga J, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clinical Science. 2007.

  13. Rodríguez-Ulloa A, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Frontiers in Pharmacology. 2024.

  14. Chorny K, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. American Journal of Physiology. 2005.

  15. Mendoza-Marí Y, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plastic Surgery International. 2016.

  16. Fernández-Mayola M, et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. International Wound Journal. 2018.

  17. Berlanga J, et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clinical Science. 2006.

  18. Soto-Vega E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. European Journal of Pharmaceutical Sciences. 2013.

  19. FDA Warning Letter to ImprimisRx. ImprimisRx CA, Inc., dba ImprimisRx - 541375 - 03/26/2019. U.S. Food and Drug Administration. 2019.

  20. FDA Warning Letter to United Pharmacy. United Pharmacy - 553916 - 02/11/2019. U.S. Food and Drug Administration. 2019.

  21. Bellone S, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Journal of Clinical Endocrinology & Metabolism. 1995.

  22. Maghnie M, et al. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection. Journal of Clinical Endocrinology & Metabolism. 1994.

  23. GHRP-6. Wikipedia.

  24. PubChem. Ghrp-6 | C46H56N12O6 | CID 4345065. National Center for Biotechnology Information.

  25. Wren AM, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002.